More than 30 years of being in business have put Singapore-listed Medtecs International in exceptional stead this Covid year.

That's why the Singapore government has been one of its top customers this year along with the Taiwan government.

WilliamYang11.20 wideTaiwan-based Medtecs CEO William Yang on an earnings call today.These countries have for many years sourced personal protective equipment (PPE) for their national stockpiles from Medtecs.


Medtecs, manufacturing out of Cambodia and the Philippines, says it is the largest PPE producer outside of China.

Medtecs gross profit margin

1Q20

2Q20

3Q20

18%

36%

53%

Yes, selling prices for its products (PPE and masks) have eased since peaking in April this year.

Currently, they are "stable" with attractive gross margins because raw material prices have pulled back sharply, and because Medtecs now sells directly to global buyers, said Medtecs CEO William Yang at an earnings call today (10 Nov).

"Even though ASPs have dropped, they have stabilised, our gross profit percentage is still high and we are getting more and more market share."

Medtecs BizModel

This year has been exceptional in that Medtecs has attracted many new long-term customers, and
business volume is looking to grow, said Mr Yang on a 3Q results earnings call.

In fact, possibly, Medtecs will have to expand production capacity.   

Stock price 

$1.02

52-week range

3 c – $1.98

Market cap

S$560 m

PE (FY20F)*

less than 3.2x

Dividend yield 

1.1%

1-year return

2,760%

Shares outstanding

549.4 m

* assumes at least S$175 m profit in FY20, based on company guidance of "record profit" in 4Q.

In Cambodia, where it produces PPE, it has unutilised land to expand production facilities on, and it can tap skilled labour which has been recently laid off by garment factories.

"We'll review the necessity to ramp up our in-house capacity. B
ut as you know, if the orders are big and for the long term, then why not do it in-house?

Customers usually order 2-3 months in advance of delivery but they also give Medtecs order forecasts for the rolling 6-12 months.

"For 2021, with or without Covid vaccine, our customers’ demand is increasing and our market, our orders are just growing," said Mr Yang. 

In the US, Medtecs will soon open its initial facility producing masks (branded Medtecs) to tap into demand arising from the President-elect's emphasis on mask-wearing.

Capex for further expansion will be well supported by the large cashflow and profitability this year.


(Based on earlier guidance, Medtecs's 4Q will be at least as strong as 3Q. In other words, the company is set to report at least US$129 million net profit this year)

"With long-term indicative orders in hand and stabilizing raw material prices, the Company expects to report record revenue and profit in the fourth quarter and financial year ending 31 December 2020." -- Medtecs (13 Oct 2020)

 

Net profit (USD)

1Q20
(actual)

2Q20
(actual)

3Q20
(actual)

4Q20 (assumed)

FY20 (assumed)

US$3.7 m

US$35 m

US$45 m

US$45 m
minimum

US$129 m (minimum)

 

Medtecs CoverU 11.20Front-line healthcare workers in a UK hospital donning Medtecs' PPE branded CoverU. Photo: The Telegraph
This year happens also to be the year Medtecs pivoted to a far more profitable business model. 

It created its own brand and sold directly to the world, moving away from doing OEM and selling to middlemen as in past years.


Thus its gross margins, especially starting from 2Q, have expanded along with the higher average selling prices (ASPs) lifted by Covid-induced demand. 

Based on the company's announcements, 2Q gross margin was 36%, increasing to 53% in 3Q. 

"For the future, we will have hundreds of hospitals buying directly from us. Now they can talk to the brand owner, to the manufacturer directly and we can develop products according to their needs," said Mr Yang.


Medtecs' corporate presentation is here. 


Comments  

0 #3 Benni 2020-11-16 20:15
The competitive edge of Medtecs is worth pointing out. As PPE is used up by clients, especially national stockpiles, the next wave of orders is automatic. There are high barriers of entry for quality PPEs that are not appreciated by investors, so their revenue continues to roll on with momentum!
Quote
0 #2 Steph 2020-11-11 11:12
I always take management's words with a pinch of salt - 99% of CEOs always sugar-coat their words.
Quote
0 #1 BOD 2020-11-11 09:11
MT has capabilities as end to end supplier for hospitals. This is a game changer for more sustainable growth. Hospitals like to deal with reputed and certified suppliers and if one supplier can assure on time supply and quality at competitive price it is a big moat. I believe MT is getting there.
Quote

Share Prices

Counter NameLastChange
AEM Holdings3.400-0.040
Avarga0.250-0.010
Avi-Tech Electronics0.425-
Best World Int.1.360-
CEI0.9600.010
China Sunsine0.475-0.010
CNMC GoldMine0.270-
CSE Global0.475-0.005
Food Empire0.605-0.005
Golden Energy0.158-0.001
GSS Energy0.059-0.002
ISDN Holdings0.415-0.010
ISOTeam0.144-0.002
IX Biopharma0.240-0.010
JB Foods0.580-
KSH Holdings0.340-0.005
Medtecs Intl0.860-0.015
Moya Asia0.069-0.003
Nordic Group0.235-0.005
Oxley Holdings0.2400.010
Procurri0.2900.010
REX International0.155-
Riverstone1.350-
Roxy-Pacific0.360-0.030
SingMedical0.260-0.005
Sri Trang Agro1.180-0.010
Straco Corp.0.500-
Sunningdale Tech1.510-
Sunpower Group0.675-0.025
The Trendlines0.093-0.004
UG Healthcare0.650-0.015
Uni-Asia Group0.625-
Yangzijiang Shipbldg0.935-0.015

NextInsight RSS

rss_2 NextInsight - Latest News

Online Now

We have 1422 guests and no members online